The TALAPRO-2 study was conducted in more than 800 patients with metastatic prostate cancer. One group received enzalutamide and talazoparib, while the other received enzalutamide and placebo.
According to the results of the study, combination therapy reduced the risk of disease progression or death by 37%. The effect was particularly high in patients with mutations in certain genes: they had a 54% lower risk of progression.
However, the combination therapy also caused moderate to severe side effects.
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.